|
FREE Cultural Competency Resources
Minority populations are more likely to develop CKD than non-minority populations. Studies show that African Americans, Native Americans, Hispanics and Asian Americans are, respectively, 4.5, 3.6, 2 and 1.6 times more likely to develop CKD than are Caucasians. Click here for free resources. |
|
CONTACT US
For resources or technical  assistance on the Chronic Kidney Disease Project, call 1.800.564.7490 and ask for a member of the CKD Team or email CKDTeam@fmqai.com. |
|
Order FREE Materials
Click on the image.  |
|
|
The Top 10 Things Pharmacists Would Like to Emphasize About ACE Inhibitor and ARB Use
 According to an article recently released by FMQAI, "compelling indications for angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) use in hypertension include diabetes, chronic kidney disease (CKD), heart failure, recurrent stroke prevention, post-myocardial infarction and high coronary disease risk."
The article provides information on dosing, adverse effects, and combination therapy. To read the article, click here. |
|
|
|
FDA Public Health Alert: Change in Heparin USP Monograph
 The U.S. Food and Drug Administration earlier this month alerted health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common blood-clotting drug.
To ensure the quality of heparin and to guard against potential contamination, the United States Pharmacopeia (USP), a nonprofit standards-setting organization, adopted new manufacturing controls for heparin, effective Oct. 1, 2009. These changes include a modification of the reference standard for the drug’s unit dose.
For the complete alert, click here or for more USP Heparin Information
http://www.usp.org/hottopics/heparin.html. Also you may visit www.fda.gov. |
|
|
|
1.4 Million
Florida adults aged 65 and older
are overweight and obese,
at risk for diabetes or pre-diabetes,
AND IN NEED OF SCREENING.
Data Source: Florida 2007 Behavioral Risk Factor Surveillance System Survey
Medicare covers Diabetes Screening Tests.
These tests are available if beneficiaries have any of the following risk factors:
·
High blood pressure
·
Dyslipidemia (history of abnormal cholesterol & triglyceride levels),
·
Obesity
·
History of high blood sugar
Medicare also covers these tests if beneficiaries have two or more of the following characteristics:
·
Age 65 or older
·
Overweight
·
Family history of diabetes (parents, brothers, sisters)
·
A history of gestational diabetes (diabetes during pregnancy) or delivery of a baby weighing more than 9 pounds.
Medicare covers 2 screening tests per year for beneficiaries diagnosed with pre-diabetes and 1 screening per year for beneficiaries previously tested but not diagnosed with pre-diabetes, or never tested.
HCPCS/CPT CODES
82947 – Glucose, quantitative, blood (except reagent strip)
82950 – Glucose, post-glucose dose (includes glucose)
82951 – Glucose Tolerance Test (GTT), three specimens (includes glucose)
ICD-9-CM CODES
V77.1 Report modifier “TS” (follow-up service) for diabetes screening where the beneficiary meets the definition of pre-diabetes.
There is no cost to eligible MEDICARE beneficiaries for the Lab Test.
no co-payment or coinsurance and no deductible.
NOTE: Beneficiaries previously diagnosed with diabetes are not eligible for this benefit.
For more information, visit the Medicare Diabetes Screening Project. |
|
|
|
"Meaningful" Progress Toward Electronic Health Information Exchange
A Message from Dr. David Blumenthal, National Coordinator for Health Information Technology
 I recently reported on our announcement of State Health Information Technology Grants and grants to establish Health Information Technology Regional Extension Centers, as authorized under the Health Information Technology for Economic and Clinical Health (HITECH) Act provisions of the American Recovery and Reinvestment Act of 2009 (the Recovery Act).
Today I want to discuss the important term “meaningful use” of electronic health records (EHRs) – both as a concept that underlies the movement toward an electronic health care environment and as a practical set of standards that will be issued as a proposed regulation by the end of 2009.
|
|
|
|
The Medicare Quality Improvement Organization
 FMQAI serves as the Medicare Quality Improvement Organization and End Stage Renal Disease Network (ESRD Network 7) for Florida. With a strong reputation as a leader in facilitating change and collaboration, FMQAI implements projects and conducts case review activities to improve care across all settings, including dialysis and transplant facilities.
|
|
